News
IRON
80.00
-3.88%
-3.23
Analysts’ Top Healthcare Picks: Asahi Intecc Co (AHICF), Disc Medicine (IRON)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: InMed Pharmaceuticals (INM), Disc Medicine (IRON) and Radnet (RDNT)
TipRanks · 5d ago
Disc Medicine Price Target Announced at $132.00/Share by Guggenheim
Dow Jones · 5d ago
Guggenheim Initiates Coverage On Disc Medicine with Buy Rating, Announces Price Target of $132
Benzinga · 5d ago
Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Immunic (IMUX)
TipRanks · 6d ago
Disc Medicine initiated with a Buy at Guggenheim
TipRanks · 6d ago
Disc Medicine’s Complementary Blood-Disorder Portfolio Supports Buy Rating and $132 Price Target
TipRanks · 6d ago
Weekly Report: what happened at IRON last week (1102-1106)?
Weekly Report · 6d ago
Disc Medicine (IRON) Receives a Buy from Truist Financial
TipRanks · 11/06 15:05
Disc Medicine Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 11/06 11:51
Disc Medicine Price Target Raised to $127.00/Share From $120.00 by HC Wainwright & Co.
Dow Jones · 11/06 11:51
HC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $127
Benzinga · 11/06 11:40
Disc Medicine price target raised to $127 from $120 at H.C. Wainwright
TipRanks · 11/06 11:16
Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update
NASDAQ · 11/06 04:01
Disc Medicine Enters Sales Agreement With TD Cowen For Common Stock Offering; May Offer Common Stock Up To $189.93M Through TD Cowen
Benzinga · 11/05 22:59
Disc Medicine reports Q3 EPS ($1.53), consensus ($1.71)
TipRanks · 11/05 14:36
Disc Medicine Q3 EPS $(1.53) Beats $(1.76) Estimate
Benzinga · 11/05 14:02
Disc Medicine GAAP EPS of -$1.53 beats by $0.20
Seeking Alpha · 11/05 13:34
*Disc Medicine: Cash Runway Into 2030 >IRON
Dow Jones · 11/05 13:31
*Disc Medicine Plans Bitopertin NDA Resubmission by End of 2026 >IRON
Dow Jones · 11/05 13:31
More
Webull provides a variety of real-time IRON stock news. You can receive the latest news about Disc Medicine Inc through multiple platforms. This information may help you make smarter investment decisions.
About IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.